Together we will beat cancer

Donate

NICE recommends pembrolizumab for 1,600 more people with breast cancer

The “potentially life-saving” immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales.

Read More

Repurposing radiotherapy drugs could give immunotherapy a boost

Researchers in Southampton have found that a way to improve the effectiveness of immunotherapy in cancers that are resistant by repurposing existing drugs

Read More

How “the most advanced machine learning approach” is finding new cancer-causing mutational signatures

A team of researchers has developed a new tool to identify mutational signatures in cancer DNA that’s quickly establishing itself as the best of the best.  

Read More

NICE doesn’t recommend olaparib for patients with certain prostate cancers

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

Read More

How radiotherapy became a lifesaver – from X-rays to the proton beam

This entry is part 5 of 6 in the series Cancer Revolutionaries

Provided to more than a quarter of cancer patients, targeted radiotherapy is cutting edge, can be curative, and has come a long way from its origins.

Read More

How erectile dysfunction drugs could be the key to overcoming treatment resistance in oesophageal cancer

Researchers have found a drug that targets the tumour microenvironment that could improve treatment for certain cancers. But it might not be the kind of drug you expect. 

Read More

Cannabis, cannabinoids and cancer – the evidence so far

The current consensus is that, right now, there isn’t a large enough body of evidence to prove that cannabis (or any of its active compounds or derivatives) can reliably treat any form of cancer but the medical use of cannabis to treat cancer-related chronic pain is approved in the UK.

Read More

Immune cell count could determine whether chemotherapy is required in oropharyngeal cancer, new study finds 

A new study has found that the level of a person’s immune cells may provide an indication of whether they would benefit from chemotherapy in oropharyngeal cancer.

Read More

A new approach to cancer immunotherapy

Forty years ago, hints of a new component of the immune system caused a stir. Here, we chart the story of gamma delta T cells from discovery to clinical trials…

Read More

Aromatase inhibitors cut breast cancer recurrence in younger patients

A study by Oxford University has found that aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in both younger and older women.

Read More